Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26293326 | 0.81 | ALDH1A1 (0.32) | ALDH1A1HPGD | |
| SCHEMBL26293340 | 0.81 | CDK9 (0.32) | KDM4ESMN1; SMN2 | |
| SCHEMBL26293310 | 0.81 | HRH4 (0.36) | — | |
| SCHEMBL19055938 | 0.63 | CYP1A2 (0.46) | ALDH1A1HPGDSMN1; SMN2CYP1A2TSHR | |
| SCHEMBL19001545 | 0.63 | PDE10A (0.42) | KDM4EALDH1A1 | |
| SCHEMBL9797601 | 0.61 | TERT (0.46) | KDM4EALDH1A1GLAHPGDSMN1; SMN2 | |
| SCHEMBL694204 | 0.61 | NOS3 (0.41) | KDM4EALDH1A1GLAHPGDSMN1; SMN2 | |
| SCHEMBL16884036 | 0.60 | CDK2 (0.44) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18544785 | 0.58 | HTT (0.55) | KDM4EALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL22004963 | 0.57 | PIK3CB (0.35) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | UTRN, ZFX, CBX6 | KDM4E 687/4885ALDH1A1 2505/4885GLA 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.